SCHEMBL2269271

SCHEMBL2269271

CC(C)(C)OC(=O)N1CCC(C(=O)N2CCOCC2)(c2ccccc2)CC1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.63
TSHR P16473 3/20 0.60
ALOX15 P16050 1/20 0.60
ATM Q13315 1/20 0.60
ALDH1A1 P00352 2/20 0.56
LMNA P02545 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
USP2 O75604 1/20 0.56
CYP3A4 P08684 1/20 0.52
CYP2C19 P33261 1/20 0.52
HSD11B1 P28845 2/20 0.50
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
GPR119 Q8TDV5 1/20 0.47
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TACR1 P25103 1/20 0.46
OPRD1 P41143 1/20 0.46
OPRK1 P41145 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4630789 0.89 HSD11B1 (0.65) SMN1; SMN2TSHRALOX15ATMALDH1A1
SCHEMBL2477283 0.88 HSD11B1 (0.66) SMN1; SMN2TSHRALOX15ATMALDH1A1
SCHEMBL7466581 0.86 TSHR (0.53) SMN1; SMN2TSHRALOX15ATMALDH1A1
SCHEMBL972474 0.83 TSHR (0.65) TSHRALOX15ATMCYP2C19HSD11B1
SCHEMBL8257825 0.83 SMN1; SMN2 (0.69) SMN1; SMN2TSHRALDH1A1LMNANPSR1
SCHEMBL13543984 0.82 TSHR (0.64) TSHRALOX15ATMHSD11B1KMT2A
SCHEMBL5371532 0.82 SMN1; SMN2 (0.76) SMN1; SMN2TSHRALDH1A1LMNANPSR1
SCHEMBL6543685 0.81 TSHR (0.70) TSHRALOX15ATMHSD11B1GPR119
SCHEMBL6543780 0.81 TSHR (0.63) TSHRALOX15ATMHSD11B1KMT2A
SCHEMBL4631302 0.81 ALDH1A1 (0.60) SMN1; SMN2TSHRALOX15ATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP disclosed
US-7994196-B2 Indazole compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173537-A1 Indazole compound and pharmaceutical use thereof CYP3A5, CYP3A43, TP53 SMN1; SMN2 4550/4885TSHR 4692/4885ALOX15 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.